SynthesisHerz2020
Associations between nine candidate genetic polymorphisms with coronary heart disease : A meta-analysis.
Synthesis in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic variants in CYP11B1 influence the susceptibility to coronary heart disease.BMC medical genomics · 2022Article
- Rs420137, rs386360 and rs7763726 polymorphisms in fibronectin type III domain containing 1 are associated with susceptibility to coronary heart disease: Analysis in the Han population.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to obtain a more accurate assessment of the potential association between nine genetic polymorphisms and the risk of coronary heart disease (CHD).
methodsA literature search was performed in PubMed, Embase, OVID, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure (CNKI) databases to identify eligible studies. We analyzed the odds ratios (OR) and 95% confidence intervals (CI) to assess the strength of the associations.
resultsA significant association was found between the PON1 -108C/T polymorphism and CHD risk (TT vs. CC: OR = 1.67, 95% CI = 1.14-2.47, p = 0.009; CT vs. CC: OR = 1.47, 95% CI = 1.17-1.85, p = 0.001; [TT + CT] vs. CC: OR = 1.56, 95% CI = 1.18-2.06, p = 0.002; T allele vs. C allele: OR = 1.28, 95%CI = 1.06-1.54, p = 0.011). There was a significant association between the hOGG1 +1245C/G polymorphism and CHD (GG vs. CC: OR = 2.33, 95% CI: 1.19-4.56, p = 0.014; CG vs. CC: OR = 1.36, 95% CI: 1.01-1.83, p = 0.046; [GG + CG] vs. CC: OR = 1.46, 95% CI: 1.10-1.94, p = 0.010; GG vs. [CC+CG]: OR = 2.11, 95% CI: 1.08-4.10, p = 0.028; G allele vs. C allele: OR = 1.45, 95% CI: 1.14-1.84, p = 0.002). The results also showed a statistically significant association of the SCARB1 +1050C/T polymorphism with CHD (TT vs. CC: OR = 1.30, 95% CI = 1.04-1.62, p = 0.022). Meta-analyses of the other six polymorphisms suggested a lack of any association with CHD risk.
conclusionOur results show that the susceptibility to CHD was associated with three polymorphisms: PON1 -108C/T, hOGG1 +1245C/G, and SCARB1 +1050C/T.
Indexed as
Identifiers
31041492What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.